BNT116 is an investigational mRNA-based vaccine developed by BioNTech targeting six tumor-associated antigens frequently expressed in NSCLC.
The new RET cohort of the BioNTech’s BNT116 mRNA cancer vaccine trial (NCT05142189), is currently available at Johns Hopkins and MD Anderson Cancer Center.
Johns Hopkins
The Johns Hopkins site initially included six slots for the RET cohort.
Patients interested in the trial can contact the Johns Hopkins New Patient Office at 410-955-8964 or email ThoracicCancerTrials@jhmi.edu.
IMPORTANT: Under the current protocol at Johns Hopkins, measurable disease is no longer required for enrollment.
MD Anderson Cancer Center
As of August 17, 2026, two spots are currently available for patients with RET-positive cancer. Additional are expected to be available once safety has been confirmed in these previous 2 spots.
The current treatment schedule consists of weekly infusions for seven weeks, followed by infusions every three weeks for up to two years. The trial also provides some financial support for travel.
Patients may be eligible if they are currently receiving a RET-targeted therapy (RET TKI) and have stable disease or disease control with measurable disease. Importantly, patients cannot enroll at the time of disease progression and must have been stable on a RET inhibitor for at least four weeks.
IMPORTANT: The requirement for measurable disease is currently under review at MD Anderson.
Patients interested in the MD Anderson trial can contact:
Phone: 1-877-MDA-6789 Study #: 2025-0372
For general questions about clinical trials: 1-855-807-2462
Find the clinical trial here.
